These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 38807690)

  • 21. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
    Sousa TR; Rema J; Machado S; Novais F
    Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psilocybin modulation of time-varying functional connectivity is associated with plasma psilocin and subjective effects.
    Olsen AS; Lykkebo-Valløe A; Ozenne B; Madsen MK; Stenbæk DS; Armand S; Mørup M; Ganz M; Knudsen GM; Fisher PM
    Neuroimage; 2022 Dec; 264():119716. PubMed ID: 36341951
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Disentangling the acute subjective effects of classic psychedelics from their enduring therapeutic properties.
    Atiq MA; Baker MR; Voort JLV; Vargas MV; Choi DS
    Psychopharmacology (Berl); 2024 May; ():. PubMed ID: 38743110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Changes in global and thalamic brain connectivity in LSD-induced altered states of consciousness are attributable to the 5-HT2A receptor.
    Preller KH; Burt JB; Ji JL; Schleifer CH; Adkinson BD; Stämpfli P; Seifritz E; Repovs G; Krystal JH; Murray JD; Vollenweider FX; Anticevic A
    Elife; 2018 Oct; 7():. PubMed ID: 30355445
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
    Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
    PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Psychedelia: The interplay of music and psychedelics.
    Jerotic K; Vuust P; Kringelbach ML
    Ann N Y Acad Sci; 2024 Jan; 1531(1):12-28. PubMed ID: 37983198
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serotonergic psychedelics for depression: What do we know about neurobiological mechanisms of action?
    Husain MI; Ledwos N; Fellows E; Baer J; Rosenblat JD; Blumberger DM; Mulsant BH; Castle DJ
    Front Psychiatry; 2022; 13():1076459. PubMed ID: 36844032
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Systematic Review of the Neurocognitive Effects of Psychedelics in Healthy Populations: Implications for Depressive Disorders and Post-Traumatic Stress Disorder.
    Velit-Salazar MR; Shiroma PR; Cherian E
    Brain Sci; 2024 Mar; 14(3):. PubMed ID: 38539636
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Psychedelics and Neuroplasticity: A Systematic Review Unraveling the Biological Underpinnings of Psychedelics.
    de Vos CMH; Mason NL; Kuypers KPC
    Front Psychiatry; 2021; 12():724606. PubMed ID: 34566723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of Psychedelics in Treatment-Resistant Depression.
    Kamal S; Jha MK; Radhakrishnan R
    Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychedelics, Meditation, and Self-Consciousness.
    Millière R; Carhart-Harris RL; Roseman L; Trautwein FM; Berkovich-Ohana A
    Front Psychol; 2018; 9():1475. PubMed ID: 30245648
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications.
    Kraehenmann R
    Curr Neuropharmacol; 2017; 15(7):1032-1042. PubMed ID: 28625125
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Is the Requirement for First-Person Experience of Psychedelic Drugs a Justified Component of a Psychedelic Therapist's Training?
    Emmerich N; Humphries B
    Camb Q Healthc Ethics; 2023 Mar; ():1-10. PubMed ID: 36861394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The acute effects of classic psychedelics on memory in humans.
    Healy CJ
    Psychopharmacology (Berl); 2021 Mar; 238(3):639-653. PubMed ID: 33420592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Beating pain with psychedelics: Matter over mind?
    Elman I; Pustilnik A; Borsook D
    Neurosci Biobehav Rev; 2022 Mar; 134():104482. PubMed ID: 34922987
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Microdosing psychedelics: Motivations, subjective effects and harm reduction.
    Lea T; Amada N; Jungaberle H; Schecke H; Klein M
    Int J Drug Policy; 2020 Jan; 75():102600. PubMed ID: 31778967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Psychedelics in Treating Anxiety Disorders.
    Feulner L; Sermchaiwong T; Rodland N; Galarneau D
    Ochsner J; 2023; 23(4):315-328. PubMed ID: 38143548
    [No Abstract]   [Full Text] [Related]  

  • 38. The unique neural signature of your trip: Functional connectome fingerprints of subjective psilocybin experience.
    Tolle HM; Farah JC; Mallaroni P; Mason NL; Ramaekers JG; Amico E
    Netw Neurosci; 2024; 8(1):203-225. PubMed ID: 38562294
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human behavioral pharmacology of psychedelics.
    Strickland JC; Johnson MW
    Adv Pharmacol; 2022; 93():105-132. PubMed ID: 35341564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.
    Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W
    Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.